National Institute for Health and Care Excellence

[Familial hypercholesterolaemia](https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0825/documents) (2017)   
NICE guideline CG71.1 – consultation on research recommendations

Stakeholder consultation comments form

Please email your completed form to [FHSCupdate@nice.org.uk](mailto:FHSCupdate@nice.org.uk)

**The consultation period closes at 5PM on 09 June 2017**

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in reviewing NICE guidelines.

If you wish to draw our attention to published studies, please supply the full reference.

|  |  |
| --- | --- |
| Stakeholder details | |
| NICE is unable to accept comments from non-registered organisations.  If you wish your comments to be considered please register via the [NICE website](http://www.nice.org.uk/get-involved/stakeholder-registration) or contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. | |
| Stakeholder organisation |  |
| Name of commentator |  |
|  | |
| Should this research recommendation stand?  What is the clinical effectiveness and safety of differing doses of lipid-modifying therapy in children with FH? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What are the appropriate indications, effectiveness and safety of LDL apheresis in people with heterozygous FH? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What are the implications of FH for the safety of a mother during pregnancy and what are the risks of fetal malformations attributable to pharmacological therapies? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What is the utility of routine cardiovascular evaluation for asymptomatic people with FH? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |

|  |  |
| --- | --- |
| Should this research recommendation stand?  What is the clinical and cost- effectiveness of using different thresholds of LDL-C concentration in primary care case- finding? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |
|  |  |
| Should this research recommendation stand?  What are the long term effects of statin therapy on sub-clinical atherosclerosis in children with FH who are treated with statin therapy? | |
| Overall response | Comments |
| Yes / No | Please add comments |
|  | Please use a separate row for each major point you wish us to address. |
|  | Please add more rows to the table if necessary. |

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.